Meda, whose products include several nasal sprays and inhalers, has announced that Jörg-Thomas Dierks will replace Anders Lönner as CEO after Lönner decided to step down. Dierks joined Meda in 2005 and had served as Chief Operating Officer since then.
Meda Chairman of the Board Bert Åke Eriksson said, “Anders Lönner has done outstanding work during his last 14 years as CEO of Meda. With his unique business skills, he has transformed Meda from a small, insignificant distributor in Scandinavia to a major global pharmaceutical company. The board wishes to express its sincere thanks to Anders Lönner.”
Lönner commented, ”Every journey has to end. I’m very glad to be placing the organization in the hands of Jörg-Thomas, who is highly competent, experienced, and has strong organizational support. Meda has a strong portfolio of new products, and its focus now will be to optimize the marketing of these products as opposed to acquisition of new products. As a result, this is a good time to make this transition. As for me, I will be spending my time with own and associated companies in the pharmaceutical area.”
Meda’s products include Astepro and Dymista nasal sprays and several Novolizer DPIs. The company also recently acquired Acton Pharmaceuticals, whose products include Aerospan MDI and Nasacort HFA.
Read the Meda press release.
